Natixis Novavax Inc Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$4.8 - $7.67 $17,025 - $27,205	-3,547 Reduced 85.99%	578 $2,000
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $28,091 - $40,177	4,125 New	4,125 $29,000
Q4 2022 Feb 13, 2023	SELL	$8.86 - $25.04 $13,759 - $38,887	-1,553 Reduced 0.36%	430,000 $4.42 Million
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $6.99 Million - $29.3 Million	384,280 Added 812.9%	431,553 $7.86 Million
Q2 2022 Aug 12, 2022	BUY	$36.28 - $75.29 $1.72 Million - $3.56 Million	47,273 New	47,273 $2.43 Million
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $152,220 - $311,950	-2,183 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $293,744 - $475,828	2,183 New	2,183 $312,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.